Media coverage about ARGENX SE-ADR (NASDAQ:ARGX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ARGENX SE-ADR earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.996858993288 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

A number of equities research analysts have weighed in on ARGX shares. Zacks Investment Research downgraded shares of ARGENX SE-ADR from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Cowen and Company reiterated a “buy” rating on shares of ARGENX SE-ADR in a research note on Thursday, August 24th.

Shares of ARGENX SE-ADR (ARGX) traded up $0.01 during trading hours on Friday, hitting $23.21. 24,920 shares of the stock traded hands, compared to its average volume of 37,658. ARGENX SE-ADR has a 52 week low of $17.33 and a 52 week high of $27.25.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Insider Buying and Selling by Quarter for ARGENX SE-ADR (NASDAQ:ARGX)

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with Analyst Ratings Network's FREE daily email newsletter.